biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics
Inhibikase Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Wilmington, USA HQ
29 Employees
Public company Type
IKT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmington, USA
- Employees
- 29
- Programs
- 4
- Drugs
- 5
- Patents
- 9
Inhibikase Therapeutics projects
4 ClinicalTrials.gov programs sponsored by Inhibikase Therapeutics.
Inhibikase Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Inhibikase Therapeutics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.